nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—CYP3A5—Ifosfamide—testicular cancer	0.161	0.231	CbGbCtD
Rivaroxaban—ABCB1—Dactinomycin—testicular cancer	0.0888	0.127	CbGbCtD
Rivaroxaban—CYP3A5—Etoposide—testicular cancer	0.077	0.11	CbGbCtD
Rivaroxaban—CYP3A4—Ifosfamide—testicular cancer	0.0628	0.0901	CbGbCtD
Rivaroxaban—ABCB1—Vinblastine—testicular cancer	0.0556	0.0797	CbGbCtD
Rivaroxaban—ABCB1—Cisplatin—testicular cancer	0.051	0.0731	CbGbCtD
Rivaroxaban—ABCB1—Etoposide—testicular cancer	0.0501	0.0718	CbGbCtD
Rivaroxaban—ABCB1—Doxorubicin—testicular cancer	0.0342	0.049	CbGbCtD
Rivaroxaban—CYP3A4—Vinblastine—testicular cancer	0.0333	0.0478	CbGbCtD
Rivaroxaban—ABCB1—Methotrexate—testicular cancer	0.0331	0.0475	CbGbCtD
Rivaroxaban—CYP3A4—Etoposide—testicular cancer	0.03	0.043	CbGbCtD
Rivaroxaban—CYP3A4—Doxorubicin—testicular cancer	0.0205	0.0294	CbGbCtD
Rivaroxaban—Blood creatinine increased—Epirubicin—testicular cancer	0.000565	0.00187	CcSEcCtD
Rivaroxaban—Tachycardia—Cisplatin—testicular cancer	0.000563	0.00186	CcSEcCtD
Rivaroxaban—Asthenia—Bleomycin—testicular cancer	0.000562	0.00186	CcSEcCtD
Rivaroxaban—Skin disorder—Cisplatin—testicular cancer	0.000561	0.00186	CcSEcCtD
Rivaroxaban—Osteoarthritis—Doxorubicin—testicular cancer	0.000558	0.00185	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Doxorubicin—testicular cancer	0.000558	0.00185	CcSEcCtD
Rivaroxaban—Pain in extremity—Doxorubicin—testicular cancer	0.000558	0.00185	CcSEcCtD
Rivaroxaban—Pruritus—Bleomycin—testicular cancer	0.000554	0.00183	CcSEcCtD
Rivaroxaban—Feeling abnormal—Ifosfamide—testicular cancer	0.000552	0.00183	CcSEcCtD
Rivaroxaban—Chest pain—Etoposide—testicular cancer	0.000552	0.00183	CcSEcCtD
Rivaroxaban—Nausea—Vinblastine—testicular cancer	0.000551	0.00182	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Epirubicin—testicular cancer	0.000551	0.00182	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000548	0.00181	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000547	0.00181	CcSEcCtD
Rivaroxaban—Discomfort—Etoposide—testicular cancer	0.000545	0.0018	CcSEcCtD
Rivaroxaban—Hypotension—Cisplatin—testicular cancer	0.000539	0.00179	CcSEcCtD
Rivaroxaban—Hypersensitivity—Dactinomycin—testicular cancer	0.000538	0.00178	CcSEcCtD
Rivaroxaban—Urticaria—Ifosfamide—testicular cancer	0.000532	0.00176	CcSEcCtD
Rivaroxaban—Abdominal pain—Ifosfamide—testicular cancer	0.000529	0.00175	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Etoposide—testicular cancer	0.000529	0.00175	CcSEcCtD
Rivaroxaban—Infection—Etoposide—testicular cancer	0.000525	0.00174	CcSEcCtD
Rivaroxaban—Asthenia—Dactinomycin—testicular cancer	0.000524	0.00173	CcSEcCtD
Rivaroxaban—Blood creatinine increased—Doxorubicin—testicular cancer	0.000523	0.00173	CcSEcCtD
Rivaroxaban—Tachycardia—Etoposide—testicular cancer	0.000516	0.00171	CcSEcCtD
Rivaroxaban—Dyspnoea—Cisplatin—testicular cancer	0.000515	0.0017	CcSEcCtD
Rivaroxaban—Skin disorder—Etoposide—testicular cancer	0.000514	0.0017	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Doxorubicin—testicular cancer	0.00051	0.00169	CcSEcCtD
Rivaroxaban—Angina pectoris—Epirubicin—testicular cancer	0.000508	0.00168	CcSEcCtD
Rivaroxaban—Diarrhoea—Dactinomycin—testicular cancer	0.0005	0.00165	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000498	0.00165	CcSEcCtD
Rivaroxaban—Vomiting—Bleomycin—testicular cancer	0.000498	0.00165	CcSEcCtD
Rivaroxaban—Infestation NOS—Methotrexate—testicular cancer	0.000497	0.00164	CcSEcCtD
Rivaroxaban—Infestation—Methotrexate—testicular cancer	0.000497	0.00164	CcSEcCtD
Rivaroxaban—Hypotension—Etoposide—testicular cancer	0.000494	0.00164	CcSEcCtD
Rivaroxaban—Rash—Bleomycin—testicular cancer	0.000494	0.00163	CcSEcCtD
Rivaroxaban—Pain—Cisplatin—testicular cancer	0.000494	0.00163	CcSEcCtD
Rivaroxaban—Dermatitis—Bleomycin—testicular cancer	0.000493	0.00163	CcSEcCtD
Rivaroxaban—Hypersensitivity—Ifosfamide—testicular cancer	0.000493	0.00163	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000492	0.00163	CcSEcCtD
Rivaroxaban—Renal failure—Methotrexate—testicular cancer	0.000488	0.00162	CcSEcCtD
Rivaroxaban—Asthenia—Ifosfamide—testicular cancer	0.00048	0.00159	CcSEcCtD
Rivaroxaban—Feeling abnormal—Cisplatin—testicular cancer	0.000476	0.00157	CcSEcCtD
Rivaroxaban—Pruritus—Ifosfamide—testicular cancer	0.000474	0.00157	CcSEcCtD
Rivaroxaban—Haematuria—Methotrexate—testicular cancer	0.000473	0.00157	CcSEcCtD
Rivaroxaban—Dyspnoea—Etoposide—testicular cancer	0.000471	0.00156	CcSEcCtD
Rivaroxaban—Angina pectoris—Doxorubicin—testicular cancer	0.00047	0.00155	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Methotrexate—testicular cancer	0.00047	0.00155	CcSEcCtD
Rivaroxaban—Epistaxis—Methotrexate—testicular cancer	0.000468	0.00155	CcSEcCtD
Rivaroxaban—Nausea—Bleomycin—testicular cancer	0.000465	0.00154	CcSEcCtD
Rivaroxaban—Infestation NOS—Epirubicin—testicular cancer	0.000465	0.00154	CcSEcCtD
Rivaroxaban—Infestation—Epirubicin—testicular cancer	0.000465	0.00154	CcSEcCtD
Rivaroxaban—Vomiting—Dactinomycin—testicular cancer	0.000465	0.00154	CcSEcCtD
Rivaroxaban—Agranulocytosis—Methotrexate—testicular cancer	0.000463	0.00153	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000461	0.00152	CcSEcCtD
Rivaroxaban—Rash—Dactinomycin—testicular cancer	0.000461	0.00152	CcSEcCtD
Rivaroxaban—Diarrhoea—Ifosfamide—testicular cancer	0.000458	0.00152	CcSEcCtD
Rivaroxaban—Renal failure—Epirubicin—testicular cancer	0.000457	0.00151	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Etoposide—testicular cancer	0.000456	0.00151	CcSEcCtD
Rivaroxaban—Fatigue—Etoposide—testicular cancer	0.000456	0.00151	CcSEcCtD
Rivaroxaban—Jaundice—Epirubicin—testicular cancer	0.000453	0.0015	CcSEcCtD
Rivaroxaban—Pain—Etoposide—testicular cancer	0.000452	0.0015	CcSEcCtD
Rivaroxaban—Constipation—Etoposide—testicular cancer	0.000452	0.0015	CcSEcCtD
Rivaroxaban—Urinary tract infection—Epirubicin—testicular cancer	0.000452	0.0015	CcSEcCtD
Rivaroxaban—Haemoglobin—Methotrexate—testicular cancer	0.000448	0.00148	CcSEcCtD
Rivaroxaban—Haemorrhage—Methotrexate—testicular cancer	0.000446	0.00148	CcSEcCtD
Rivaroxaban—Hepatitis—Methotrexate—testicular cancer	0.000446	0.00148	CcSEcCtD
Rivaroxaban—Haematuria—Epirubicin—testicular cancer	0.000443	0.00147	CcSEcCtD
Rivaroxaban—Dizziness—Ifosfamide—testicular cancer	0.000443	0.00147	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Methotrexate—testicular cancer	0.00044	0.00146	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Epirubicin—testicular cancer	0.00044	0.00145	CcSEcCtD
Rivaroxaban—Epistaxis—Epirubicin—testicular cancer	0.000438	0.00145	CcSEcCtD
Rivaroxaban—Urethral disorder—Methotrexate—testicular cancer	0.000437	0.00145	CcSEcCtD
Rivaroxaban—Sinusitis—Epirubicin—testicular cancer	0.000436	0.00144	CcSEcCtD
Rivaroxaban—Feeling abnormal—Etoposide—testicular cancer	0.000436	0.00144	CcSEcCtD
Rivaroxaban—Nausea—Dactinomycin—testicular cancer	0.000434	0.00144	CcSEcCtD
Rivaroxaban—Agranulocytosis—Epirubicin—testicular cancer	0.000434	0.00144	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Etoposide—testicular cancer	0.000432	0.00143	CcSEcCtD
Rivaroxaban—Infestation NOS—Doxorubicin—testicular cancer	0.00043	0.00142	CcSEcCtD
Rivaroxaban—Infestation—Doxorubicin—testicular cancer	0.00043	0.00142	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000426	0.00141	CcSEcCtD
Rivaroxaban—Vomiting—Ifosfamide—testicular cancer	0.000426	0.00141	CcSEcCtD
Rivaroxaban—Hypersensitivity—Cisplatin—testicular cancer	0.000425	0.00141	CcSEcCtD
Rivaroxaban—Renal failure—Doxorubicin—testicular cancer	0.000423	0.0014	CcSEcCtD
Rivaroxaban—Rash—Ifosfamide—testicular cancer	0.000422	0.0014	CcSEcCtD
Rivaroxaban—Dermatitis—Ifosfamide—testicular cancer	0.000422	0.0014	CcSEcCtD
Rivaroxaban—Erythema multiforme—Methotrexate—testicular cancer	0.000422	0.0014	CcSEcCtD
Rivaroxaban—Urticaria—Etoposide—testicular cancer	0.00042	0.00139	CcSEcCtD
Rivaroxaban—Haemoglobin—Epirubicin—testicular cancer	0.000419	0.00139	CcSEcCtD
Rivaroxaban—Jaundice—Doxorubicin—testicular cancer	0.000419	0.00139	CcSEcCtD
Rivaroxaban—Abdominal pain—Etoposide—testicular cancer	0.000418	0.00138	CcSEcCtD
Rivaroxaban—Urinary tract infection—Doxorubicin—testicular cancer	0.000418	0.00138	CcSEcCtD
Rivaroxaban—Haemorrhage—Epirubicin—testicular cancer	0.000417	0.00138	CcSEcCtD
Rivaroxaban—Hepatitis—Epirubicin—testicular cancer	0.000417	0.00138	CcSEcCtD
Rivaroxaban—Eye disorder—Methotrexate—testicular cancer	0.000417	0.00138	CcSEcCtD
Rivaroxaban—Asthenia—Cisplatin—testicular cancer	0.000414	0.00137	CcSEcCtD
Rivaroxaban—Cardiac disorder—Methotrexate—testicular cancer	0.000414	0.00137	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Epirubicin—testicular cancer	0.000412	0.00136	CcSEcCtD
Rivaroxaban—Haematuria—Doxorubicin—testicular cancer	0.00041	0.00136	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Epirubicin—testicular cancer	0.00041	0.00136	CcSEcCtD
Rivaroxaban—Urethral disorder—Epirubicin—testicular cancer	0.000409	0.00135	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000407	0.00135	CcSEcCtD
Rivaroxaban—Epistaxis—Doxorubicin—testicular cancer	0.000406	0.00134	CcSEcCtD
Rivaroxaban—Angiopathy—Methotrexate—testicular cancer	0.000404	0.00134	CcSEcCtD
Rivaroxaban—Sinusitis—Doxorubicin—testicular cancer	0.000403	0.00134	CcSEcCtD
Rivaroxaban—Immune system disorder—Methotrexate—testicular cancer	0.000403	0.00133	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Methotrexate—testicular cancer	0.000402	0.00133	CcSEcCtD
Rivaroxaban—Agranulocytosis—Doxorubicin—testicular cancer	0.000401	0.00133	CcSEcCtD
Rivaroxaban—Nausea—Ifosfamide—testicular cancer	0.000398	0.00132	CcSEcCtD
Rivaroxaban—Diarrhoea—Cisplatin—testicular cancer	0.000395	0.00131	CcSEcCtD
Rivaroxaban—Erythema multiforme—Epirubicin—testicular cancer	0.000394	0.00131	CcSEcCtD
Rivaroxaban—Eye disorder—Epirubicin—testicular cancer	0.00039	0.00129	CcSEcCtD
Rivaroxaban—Hypersensitivity—Etoposide—testicular cancer	0.00039	0.00129	CcSEcCtD
Rivaroxaban—Haemoglobin—Doxorubicin—testicular cancer	0.000388	0.00128	CcSEcCtD
Rivaroxaban—Cardiac disorder—Epirubicin—testicular cancer	0.000387	0.00128	CcSEcCtD
Rivaroxaban—Hepatitis—Doxorubicin—testicular cancer	0.000386	0.00128	CcSEcCtD
Rivaroxaban—Haemorrhage—Doxorubicin—testicular cancer	0.000386	0.00128	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Doxorubicin—testicular cancer	0.000381	0.00126	CcSEcCtD
Rivaroxaban—Asthenia—Etoposide—testicular cancer	0.000379	0.00126	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Doxorubicin—testicular cancer	0.000379	0.00126	CcSEcCtD
Rivaroxaban—Angiopathy—Epirubicin—testicular cancer	0.000379	0.00125	CcSEcCtD
Rivaroxaban—Urethral disorder—Doxorubicin—testicular cancer	0.000378	0.00125	CcSEcCtD
Rivaroxaban—Immune system disorder—Epirubicin—testicular cancer	0.000377	0.00125	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Epirubicin—testicular cancer	0.000376	0.00124	CcSEcCtD
Rivaroxaban—Back pain—Methotrexate—testicular cancer	0.000375	0.00124	CcSEcCtD
Rivaroxaban—Pruritus—Etoposide—testicular cancer	0.000374	0.00124	CcSEcCtD
Rivaroxaban—Vomiting—Cisplatin—testicular cancer	0.000367	0.00121	CcSEcCtD
Rivaroxaban—Erythema multiforme—Doxorubicin—testicular cancer	0.000365	0.00121	CcSEcCtD
Rivaroxaban—Rash—Cisplatin—testicular cancer	0.000364	0.0012	CcSEcCtD
Rivaroxaban—Dermatitis—Cisplatin—testicular cancer	0.000364	0.0012	CcSEcCtD
Rivaroxaban—Diarrhoea—Etoposide—testicular cancer	0.000362	0.0012	CcSEcCtD
Rivaroxaban—Eye disorder—Doxorubicin—testicular cancer	0.000361	0.00119	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Methotrexate—testicular cancer	0.00036	0.00119	CcSEcCtD
Rivaroxaban—Anaemia—Methotrexate—testicular cancer	0.000359	0.00119	CcSEcCtD
Rivaroxaban—Cardiac disorder—Doxorubicin—testicular cancer	0.000358	0.00119	CcSEcCtD
Rivaroxaban—Back pain—Epirubicin—testicular cancer	0.000351	0.00116	CcSEcCtD
Rivaroxaban—Angiopathy—Doxorubicin—testicular cancer	0.00035	0.00116	CcSEcCtD
Rivaroxaban—Malaise—Methotrexate—testicular cancer	0.00035	0.00116	CcSEcCtD
Rivaroxaban—Dizziness—Etoposide—testicular cancer	0.00035	0.00116	CcSEcCtD
Rivaroxaban—Muscle spasms—Epirubicin—testicular cancer	0.000349	0.00116	CcSEcCtD
Rivaroxaban—Immune system disorder—Doxorubicin—testicular cancer	0.000349	0.00115	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Doxorubicin—testicular cancer	0.000348	0.00115	CcSEcCtD
Rivaroxaban—Nausea—Cisplatin—testicular cancer	0.000343	0.00113	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Epirubicin—testicular cancer	0.000337	0.00112	CcSEcCtD
Rivaroxaban—Vomiting—Etoposide—testicular cancer	0.000336	0.00111	CcSEcCtD
Rivaroxaban—Anaemia—Epirubicin—testicular cancer	0.000336	0.00111	CcSEcCtD
Rivaroxaban—Rash—Etoposide—testicular cancer	0.000333	0.0011	CcSEcCtD
Rivaroxaban—Dermatitis—Etoposide—testicular cancer	0.000333	0.0011	CcSEcCtD
Rivaroxaban—Headache—Etoposide—testicular cancer	0.000331	0.0011	CcSEcCtD
Rivaroxaban—Chest pain—Methotrexate—testicular cancer	0.00033	0.00109	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000328	0.00109	CcSEcCtD
Rivaroxaban—Malaise—Epirubicin—testicular cancer	0.000328	0.00108	CcSEcCtD
Rivaroxaban—Discomfort—Methotrexate—testicular cancer	0.000326	0.00108	CcSEcCtD
Rivaroxaban—Syncope—Epirubicin—testicular cancer	0.000326	0.00108	CcSEcCtD
Rivaroxaban—Back pain—Doxorubicin—testicular cancer	0.000325	0.00108	CcSEcCtD
Rivaroxaban—Muscle spasms—Doxorubicin—testicular cancer	0.000323	0.00107	CcSEcCtD
Rivaroxaban—Loss of consciousness—Epirubicin—testicular cancer	0.000319	0.00106	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Methotrexate—testicular cancer	0.000317	0.00105	CcSEcCtD
Rivaroxaban—Infection—Methotrexate—testicular cancer	0.000315	0.00104	CcSEcCtD
Rivaroxaban—Nausea—Etoposide—testicular cancer	0.000314	0.00104	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Doxorubicin—testicular cancer	0.000312	0.00103	CcSEcCtD
Rivaroxaban—Nervous system disorder—Methotrexate—testicular cancer	0.000311	0.00103	CcSEcCtD
Rivaroxaban—Anaemia—Doxorubicin—testicular cancer	0.000311	0.00103	CcSEcCtD
Rivaroxaban—Chest pain—Epirubicin—testicular cancer	0.000309	0.00102	CcSEcCtD
Rivaroxaban—Skin disorder—Methotrexate—testicular cancer	0.000308	0.00102	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000307	0.00102	CcSEcCtD
Rivaroxaban—Discomfort—Epirubicin—testicular cancer	0.000305	0.00101	CcSEcCtD
Rivaroxaban—Malaise—Doxorubicin—testicular cancer	0.000303	0.001	CcSEcCtD
Rivaroxaban—Dry mouth—Epirubicin—testicular cancer	0.000302	0.001	CcSEcCtD
Rivaroxaban—Syncope—Doxorubicin—testicular cancer	0.000301	0.000997	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Epirubicin—testicular cancer	0.000296	0.000981	CcSEcCtD
Rivaroxaban—Oedema—Epirubicin—testicular cancer	0.000296	0.000981	CcSEcCtD
Rivaroxaban—Hypotension—Methotrexate—testicular cancer	0.000296	0.00098	CcSEcCtD
Rivaroxaban—Loss of consciousness—Doxorubicin—testicular cancer	0.000295	0.000978	CcSEcCtD
Rivaroxaban—Infection—Epirubicin—testicular cancer	0.000294	0.000975	CcSEcCtD
Rivaroxaban—Shock—Epirubicin—testicular cancer	0.000292	0.000965	CcSEcCtD
Rivaroxaban—Nervous system disorder—Epirubicin—testicular cancer	0.000291	0.000962	CcSEcCtD
Rivaroxaban—Tachycardia—Epirubicin—testicular cancer	0.000289	0.000957	CcSEcCtD
Rivaroxaban—Skin disorder—Epirubicin—testicular cancer	0.000288	0.000953	CcSEcCtD
Rivaroxaban—Chest pain—Doxorubicin—testicular cancer	0.000286	0.000947	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000284	0.00094	CcSEcCtD
Rivaroxaban—Discomfort—Doxorubicin—testicular cancer	0.000283	0.000936	CcSEcCtD
Rivaroxaban—Dyspnoea—Methotrexate—testicular cancer	0.000282	0.000935	CcSEcCtD
Rivaroxaban—Dry mouth—Doxorubicin—testicular cancer	0.00028	0.000926	CcSEcCtD
Rivaroxaban—Dyspepsia—Methotrexate—testicular cancer	0.000279	0.000923	CcSEcCtD
Rivaroxaban—Hypotension—Epirubicin—testicular cancer	0.000277	0.000917	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Doxorubicin—testicular cancer	0.000274	0.000908	CcSEcCtD
Rivaroxaban—Oedema—Doxorubicin—testicular cancer	0.000274	0.000908	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000273	0.000905	CcSEcCtD
Rivaroxaban—Fatigue—Methotrexate—testicular cancer	0.000273	0.000904	CcSEcCtD
Rivaroxaban—Infection—Doxorubicin—testicular cancer	0.000272	0.000902	CcSEcCtD
Rivaroxaban—Pain—Methotrexate—testicular cancer	0.000271	0.000896	CcSEcCtD
Rivaroxaban—Shock—Doxorubicin—testicular cancer	0.00027	0.000893	CcSEcCtD
Rivaroxaban—Nervous system disorder—Doxorubicin—testicular cancer	0.000269	0.00089	CcSEcCtD
Rivaroxaban—Tachycardia—Doxorubicin—testicular cancer	0.000268	0.000886	CcSEcCtD
Rivaroxaban—Skin disorder—Doxorubicin—testicular cancer	0.000266	0.000882	CcSEcCtD
Rivaroxaban—Dyspnoea—Epirubicin—testicular cancer	0.000264	0.000875	CcSEcCtD
Rivaroxaban—Feeling abnormal—Methotrexate—testicular cancer	0.000261	0.000864	CcSEcCtD
Rivaroxaban—Dyspepsia—Epirubicin—testicular cancer	0.000261	0.000864	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Methotrexate—testicular cancer	0.000259	0.000857	CcSEcCtD
Rivaroxaban—Hypotension—Doxorubicin—testicular cancer	0.000256	0.000848	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000256	0.000847	CcSEcCtD
Rivaroxaban—Fatigue—Epirubicin—testicular cancer	0.000256	0.000846	CcSEcCtD
Rivaroxaban—Pain—Epirubicin—testicular cancer	0.000253	0.000839	CcSEcCtD
Rivaroxaban—Constipation—Epirubicin—testicular cancer	0.000253	0.000839	CcSEcCtD
Rivaroxaban—Urticaria—Methotrexate—testicular cancer	0.000252	0.000833	CcSEcCtD
Rivaroxaban—Abdominal pain—Methotrexate—testicular cancer	0.00025	0.000829	CcSEcCtD
Rivaroxaban—Dyspnoea—Doxorubicin—testicular cancer	0.000245	0.000809	CcSEcCtD
Rivaroxaban—Feeling abnormal—Epirubicin—testicular cancer	0.000244	0.000808	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Epirubicin—testicular cancer	0.000242	0.000802	CcSEcCtD
Rivaroxaban—Dyspepsia—Doxorubicin—testicular cancer	0.000241	0.000799	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000237	0.000784	CcSEcCtD
Rivaroxaban—Fatigue—Doxorubicin—testicular cancer	0.000236	0.000783	CcSEcCtD
Rivaroxaban—Urticaria—Epirubicin—testicular cancer	0.000235	0.000779	CcSEcCtD
Rivaroxaban—Constipation—Doxorubicin—testicular cancer	0.000235	0.000776	CcSEcCtD
Rivaroxaban—Pain—Doxorubicin—testicular cancer	0.000235	0.000776	CcSEcCtD
Rivaroxaban—Abdominal pain—Epirubicin—testicular cancer	0.000234	0.000776	CcSEcCtD
Rivaroxaban—Hypersensitivity—Methotrexate—testicular cancer	0.000233	0.000772	CcSEcCtD
Rivaroxaban—Asthenia—Methotrexate—testicular cancer	0.000227	0.000752	CcSEcCtD
Rivaroxaban—Feeling abnormal—Doxorubicin—testicular cancer	0.000226	0.000748	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000224	0.000742	CcSEcCtD
Rivaroxaban—Pruritus—Methotrexate—testicular cancer	0.000224	0.000742	CcSEcCtD
Rivaroxaban—Hypersensitivity—Epirubicin—testicular cancer	0.000218	0.000723	CcSEcCtD
Rivaroxaban—Urticaria—Doxorubicin—testicular cancer	0.000218	0.000721	CcSEcCtD
Rivaroxaban—Abdominal pain—Doxorubicin—testicular cancer	0.000217	0.000718	CcSEcCtD
Rivaroxaban—Diarrhoea—Methotrexate—testicular cancer	0.000217	0.000717	CcSEcCtD
Rivaroxaban—Asthenia—Epirubicin—testicular cancer	0.000213	0.000704	CcSEcCtD
Rivaroxaban—Pruritus—Epirubicin—testicular cancer	0.00021	0.000694	CcSEcCtD
Rivaroxaban—Dizziness—Methotrexate—testicular cancer	0.000209	0.000693	CcSEcCtD
Rivaroxaban—Diarrhoea—Epirubicin—testicular cancer	0.000203	0.000671	CcSEcCtD
Rivaroxaban—Hypersensitivity—Doxorubicin—testicular cancer	0.000202	0.000669	CcSEcCtD
Rivaroxaban—Vomiting—Methotrexate—testicular cancer	0.000201	0.000667	CcSEcCtD
Rivaroxaban—Rash—Methotrexate—testicular cancer	0.0002	0.000661	CcSEcCtD
Rivaroxaban—Dermatitis—Methotrexate—testicular cancer	0.0002	0.00066	CcSEcCtD
Rivaroxaban—Headache—Methotrexate—testicular cancer	0.000198	0.000657	CcSEcCtD
Rivaroxaban—Asthenia—Doxorubicin—testicular cancer	0.000197	0.000651	CcSEcCtD
Rivaroxaban—Dizziness—Epirubicin—testicular cancer	0.000196	0.000649	CcSEcCtD
Rivaroxaban—Pruritus—Doxorubicin—testicular cancer	0.000194	0.000642	CcSEcCtD
Rivaroxaban—Vomiting—Epirubicin—testicular cancer	0.000188	0.000624	CcSEcCtD
Rivaroxaban—Nausea—Methotrexate—testicular cancer	0.000188	0.000623	CcSEcCtD
Rivaroxaban—Diarrhoea—Doxorubicin—testicular cancer	0.000188	0.000621	CcSEcCtD
Rivaroxaban—Rash—Epirubicin—testicular cancer	0.000187	0.000619	CcSEcCtD
Rivaroxaban—Dermatitis—Epirubicin—testicular cancer	0.000187	0.000618	CcSEcCtD
Rivaroxaban—Headache—Epirubicin—testicular cancer	0.000186	0.000615	CcSEcCtD
Rivaroxaban—Dizziness—Doxorubicin—testicular cancer	0.000181	0.0006	CcSEcCtD
Rivaroxaban—Nausea—Epirubicin—testicular cancer	0.000176	0.000583	CcSEcCtD
Rivaroxaban—Vomiting—Doxorubicin—testicular cancer	0.000174	0.000577	CcSEcCtD
Rivaroxaban—Rash—Doxorubicin—testicular cancer	0.000173	0.000572	CcSEcCtD
Rivaroxaban—Dermatitis—Doxorubicin—testicular cancer	0.000173	0.000572	CcSEcCtD
Rivaroxaban—Headache—Doxorubicin—testicular cancer	0.000172	0.000569	CcSEcCtD
Rivaroxaban—Nausea—Doxorubicin—testicular cancer	0.000163	0.000539	CcSEcCtD
